09:53 AM EST, 11/19/2025 (MT Newswires) -- DexCom ( DXCM ) said Wednesday that the US Food and Drug Administration has approved the Dexcom Smart Basal insulin dosing optimizer for adult patients with type 2 diabetes.

The company said it will add the optimizer to its Dexcom G7 15 Day continuous glucose monitoring system after its launch in the US. The optimizer will use the Dexcom G7 15 Day sensor data and logged doses to determine personalized daily insulin dose recommendations for users, DexCom ( DXCM ) said.

DexCom ( DXCM ) also said it is working on bringing Dexcom Smart Basal to international markets in the future.

Price: 59.61, Change: -0.56, Percent Change: -0.93